The nocebo effect of drugs
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
While the placebo effect has been studied for a long time, much less is known about its negative counterpart, named the nocebo effect. However, it may be of particular importance because of its impact on the treatment outcomes and public health. We conducted a review on the nocebo effect using PubMed and other databases up to July 2014. The nocebo effect refers by definition to the induction or the worsening of symptoms induced by sham or active therapies. Examples are numerous and concerns both clinical trials and daily practice. The underlying mechanisms are, on one hand, psychological (conditioning and negative expectations) and, on the other hand, neurobiological (role of cholecystokinin, endogenous opioids and dopamine). Nocebo effects can modulate the outcome of a given therapy in a negative way, as do placebo effects in a positive way. The verbal and nonverbal communications of physicians contain numerous unintentional negative suggestions that may trigger a nocebo response. This raises the important issue of how physicians can at the same time obtain informed consent and minimize nocebo‐related risks. Every physician has to deal with this apparent contradiction between primum non nocere and to deliver truthful information about risks. Meticulous identification of patients at risk, information techniques such as positive framing, contextualized informed consent, and even noninformation, is valuable.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
THE MECHANISM OF PLACEBO ANALGESIA
Levine, J., Gordon, N., & Fields, H. (1978) · The Lancet · doi:10.1016/s0140-6736(78)92762-9 · Cited by 1,094
Dispositional Optimism and Coping: A Meta-Analytic Review
Nes, L. S., & Segerstrom, S. C. (2006) · Personality and Social Psychology Review · doi:10.1207/s15327957pspr1003_3 · Cited by 1,000 · cited 2×
“These expectations depend on the patient himself, the most important personality trait influencing on expectancy being optimism or pessimism, defined as a generalized and relatively stable expectancy for positive or negative future outcomes (Nes and Segerstrom 2006) and the most important illness being anxiety–depress…”
BackgroundBingel, U., Wanigasekera, V., Wiech, K., Ni Mhuircheartaigh, R., Lee, M. C., Ploner, M., & Tracey, I. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001244 · Cited by 810
Nonspecific medication side effects and the nocebo phenomenon
Barsky, A. J. (2002) · JAMA · doi:10.1001/jama.287.5.622 · Cited by 784
When words are painful: unraveling the mechanisms of the nocebo effect
Benedetti, F., Lanotte, M., Lopiano, L., & Colloca, L. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2007.02.020 · Cited by 636 · cited 2×
“However, some recent studies on healthy volunteers and some others on animals have shed new light on this phenomenon (Benedetti et al. 2007).”
BackgroundPlacebos and painkillers: is mind as real as matter?
Colloca, L., & Benedetti, F. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1705 · Cited by 465
Atlas, L. Y., & Wager, T. D. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.03.039 · Cited by 463
The biochemical and neuroendocrine bases of the hyperalgesic nocebo effect
Benedetti, F., Amanzio, M., Vighetti, S., & Asteggiano, G. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2947-06.2006 · Cited by 419 · cited 2×
“Both nocebo hyperalgesia and HPA hyperactivity were antagonized by the benzodiazepine diazepam, suggesting that anxiety played a major role in these effects (Benedetti et al. 2006).”
BackgroundMeta-analysis of the placebo response in antidepressant trials.
Rief, W., Nestoriuc, Y., Weiss, S., Welzel, E., Barsky, A. J., & Hofmann, S. G. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.01.029 · Cited by 346 · cited 1×
“A systematic review from 143 placebo-controlled trials of antidepressant medications (with data from over 12,000 subjects) also showed that the adverse effects reported in those receiving placebo closely related to the corresponding drug in the trial (Rief et al. 2009b).”
BackgroundNocebo effects, patient–clinician communication, and therapeutic outcomes
Colloca, L., & Finniss, D. (2012) · JAMA · doi:10.1001/jama.2012.115 · Cited by 326 · cited 4×
“Furthermore, the process of tailoring information should account for what the patient wants to know and what the patient has already learned about his or her condition given the widespread access to information about treatments and their adverse effects (Colloca and Finniss 2012).”
BackgroundInfluential
Research works printed but not linked: 69
- 10.1016/j.pain.2009.07.010 · DOI · Paper page
- 10.1007/s10194-007-0360-4 · DOI
- 10.7326/0003-4819-130-11-199906010-00016 · DOI · Paper page
- 10.1016/j.jams.2012.03.001 · DOI
- 10.1016/j.jbspin.2010.08.006 · DOI
- 10.1016/S1297-319X(00)00225-6 · DOI
- 10.1002/jclp.20131 · DOI · Paper page
- 10.1016/S0006-3223(00)00966-5 · DOI
- 10.1016/j.jpain.2012.12.011 · DOI
- 10.1111/1753-6405.12066 · DOI
- 10.3399/bjgp14X677851 · DOI · Paper page
- 10.1111/j.2044-8325.1979.tb00444.x · DOI
- 10.1098/rstb.2010.0399 · DOI · Paper page
- 10.1097/PSY.0b013e3182294a50 · DOI · Paper page
- 10.1016/S1474-4422(04)00908-1 · DOI · Paper page
- 10.1016/j.mehy.2009.07.023 · DOI
- 10.1177/0004867412464717 · DOI · Paper page
- 10.1111/j.1745-6592.2004.tb00721.x · doi:10.1111/j.1745-6592.2004.tb00721.x
- 10.1001/archinte.163.5.592 · DOI
- 10.1136/bmj.313.7072.1624 · DOI · Paper page
- 10.1111/j.1365-2125.1995.tb04434.x · DOI · Paper page
- 10.2165/11532400-000000000-00000 · DOI
- 10.1111/j.1365-2982.2012.01950.x · DOI · Paper page
- 10.1016/j.neuron.2008.06.030 · DOI · Paper page
- 10.1136/postgradmedj-2012-131730 · DOI · Paper page
- 10.1186/2046-4053-1-54 · DOI
- 10.1098/rstb.2010.0407 · DOI · Paper page
- 10.1007/s10865-005-9040-5 · DOI
- 10.1016/j.jpain.2010.02.014 · DOI · Paper page
- 10.1159/000189628 · DOI
- Hahn RA, 1997, The nocebo phenomenon: scope and foundations. The placebo effect: an interdisciplinary exploration, 56
- 10.1006/pmed.1996.0124 · DOI · Paper page
- Häuser W, 2012, Nocebo phenomena in medicine: their relevance in everyday clinical practice, Dtsch Ärztebl Int, 109, 459
- Häuser W, 2012, Placebo and nocebo responses in randomised controlled trials of drugs applying for approval for fibromyalgia syndrome treatment: systematic review and meta‐analysis, Clin Exp Rheumatol, 30, 78
- 10.1080/08870449908407311 · DOI · Paper page
- 10.1111/j.2044-8287.2012.02071.x · DOI · Paper page
- 10.1136/bmj.38726.603310.55 · DOI · Paper page
- Kennedy WP, 1961, The nocebo reaction, Med World, 95, 203
- 10.1016/j.jpsychores.2008.09.019 · DOI
- Liccardi G, 2004, Evaluation of the nocebo effect during oral challenge in patients with adverse drug reactions, J Investig Allergol Clin Immunol, 14, 104
- 10.1016/j.neubiorev.2008.01.003 · DOI
- 10.1016/j.mehy.2011.08.029 · DOI
- 10.1007/s11017-011-9179-8 · DOI
- 10.1177/0333102410391485 · DOI
- 10.1111/j.1743-6109.2007.00563.x · DOI · Paper page
- 10.1080/08870440290001494 · DOI · Paper page
- 10.1016/S0895-4356(96)00177-1 · DOI · Paper page
- 10.1016/j.vaccine.2011.05.045 · DOI
- 10.1007/s00415-011-6197-4 · DOI
- 10.1037/0022-3514.41.2.213 · DOI
- 10.1097/00001756-200208070-00006 · DOI · Paper page
- Psaty BM, 1990, The relative risk of incident coronary heart disease associated with recently stopping the use of beta‐blockers, JAMA, 263, 1653, 10.1001/jama.1990.03440120075040 · doi:10.1001/jama.1990.03440120075040 · Paper page
- 10.1016/j.genhosppsych.2007.01.010 · DOI
- 10.1046/j.1526-4610.2003.03216.x · DOI
- 10.1016/j.envres.2008.02.003 · DOI · Paper page
- 10.1002/bem.20536 · DOI · Paper page
- 10.1016/j.jpainsymman.2012.12.005 · DOI
- 10.1001/archgenpsychiatry.2007.34 · DOI · Paper page
- 10.1016/j.ijheh.2010.05.001 · DOI
- 10.1016/j.homp.2010.02.001 · DOI
- Terracciano A, 2014, Are personality traits associated with white‐coat and masked hypertension?, J Hypertens, 1, 16
- 10.1213/ANE.0b013e3181cc5727 · DOI · Paper page
- 10.1016/j.dld.2010.02.005 · DOI
- Voelker R, 1996, Nocebos contribute to host of ills, JAMA, 275, 345, 10.1001/jama.1996.03530290015007 · doi:10.1001/jama.1996.03530290015007
- 10.1016/j.pain.2013.04.041 · DOI · Paper page
- Weissenfeld J, 2010, The nocebo effect: a reason for patients non‐adherence to generic substitution?, Pharm‐ Int J Pharm Sci, 65, 451
- 10.1080/15265161.2011.652798 · DOI · Paper page
- 10.1016/j.athoracsur.2012.10.048 · DOI
- 10.1016/j.jpsychores.2012.12.002 · DOI · Paper page
Cited by
Aday, J. S., Heifets, B. D., Pratscher, S. D., Bradley, E., Rosen, R., & Woolley, J. D. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06123-7 · Cited by 237
Antidépresseurs et tolérance : déterminants et prise en charge des principaux effets indésirables
David, D. J., & Gourion, D. (2016) · L'Encéphale · doi:10.1016/j.encep.2016.05.006 · Cited by 105
Zis, P., Shafique, F., Hadjivassiliou, M., Blackburn, D., Venneri, A., Iliodromiti, S., Mitsikostas, D.-D., & Sarrigiannis, P. G. (2020) · Neuromodulation: Technology at the Neural Interface · doi:10.1111/ner.12946 · Cited by 77
Corsi, N., Emadi Andani, M., Tinazzi, M., & Fiorio, M. (2016) · Scientific Reports · doi:10.1038/srep30671 · Cited by 44
de Guingand, D. L., Palmer, K. R., Snow, R. J., Davies-Tuck, M. L., & Ellery, S. J. (2020) · Nutrients · doi:10.3390/nu12061780 · Cited by 35
Statin‐associated muscle symptoms—A review: Individualizing the approach to optimize care
Wiggins, B. S., Backes, J. M., & Hilleman, D. (2022) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2681 · Cited by 17
Metadata
- Authors
- Planès, S., Villier, C., & Mallaret, M.
- Venue
- Pharmacology Research & Perspectives
- Publisher
- Wiley
- Published
- 2016-03-17
- Volume
- 4
- Issue
- 2
- Pages
- e00208-e00208
- ISSN
- 2052-1707 (ISSN-L)
- OpenAlex
- W2330425005
- Cited by
- 172
- References
- 17
- FWCI
- 11.95
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.